Course and treatment of chronic hepatitis E virus infection in lung transplant recipients

Transplant Infectious Disease

Volumn 16, Issue 2, 2014, Pages 333-339

  Pischke, S ^a,b   Greer, M ^a,b   Hardtke, S ^a   Bremer, B ^a   Gisa, A ^a   Lehmann, P ^a   Haverich, A ^a   Welte, T ^a   Manns, M P ^a,b   Wedemeyer, H ^a,b   Gottlieb, J ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b IFB TX   (Germany)

Author keywords

Chronic infection; Hepatitis E; Lung transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; HEMOGLOBIN; HEPATITIS E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MYCOPHENOLIC ACID; PREDNISOLONE; RIBAVIRIN; TACROLIMUS; VIRUS RNA; ANTIVIRUS AGENT; IMMUNOGLOBULIN G;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHEMORADIOTHERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEART RIGHT VENTRICLE DYSPLASIA; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LOW DRUG DOSE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SCREENING; SEROPREVALENCE; TREATMENT DURATION; VIREMIA; VIRUS REPLICATION; BLOOD; CHRONIC DISEASE; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; YOUNG ADULT;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHRONIC DISEASE; FEMALE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNOGLOBULIN G; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES; VIRUS REPLICATION; YOUNG ADULT;

EID: 84897957553     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12183     Document Type: Article

References (26)

1. Aggarwal R, Jameel S. Hepatitis E. Hepatology 2011; 54: 2218-2226.
2. Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010; 376: 895-902.
3. Stoszek SK, Engle RE, Abdel-Hamid M, et al. Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities. Trans R Soc Trop Med Hyg 2006; 100: 89-94.
4. Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology 2012; 142: 1388-1397, e1381.
5. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358: 811-817.
6. Pischke S, Suneetha PV, Baechlein C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010; 16: 74-82.
7. Haagsma EB, Niesters HG, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009; 15: 1225-1228.
8. Wedemeyer H, Rybczynska J, Pischke S, Krawczynski K. Immunopathogenesis of hepatitis E virus infection. Semin Liver Dis 2013; 33: 71-78.
9. Suneetha PV, Pischke S, Schlaphoff V, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 2012; 55: 695-708.
10. Pas SD, de Man RA, Mulders C, et al. Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg Infect Dis 2012; 18: 869-872.
11. Riezebos-Brilman A, Puchhammer-Stockl E, van der Weide HY, et al. Chronic hepatitis E infection in lung transplant recipients. J Heart Lung Transplant 2012; 32: 341-346.
12. Kamar N, Rostaing L, Legrand-Abravanel F, Izopet J. How should hepatitis E virus infection be defined in organ-transplant recipients? Am J Transplant 2013; 13: 1935-1936.
13. Pischke S, Heim A, Bremer B, et al. Hepatitis E: an emerging infectious disease in Germany? Z Gastroenterol 2011; 49: 1255-1257.
14. Pischke S, Hardtke S, Bode U, et al. Ribavirin treatment of acute and chronic hepatitis E: a single center experience. Liver Int 2013; 33: 722-726.
15. Wenzel JJ, Preiss J, Schemmerer M, Huber B, Jilg W. Test performance characteristics of anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. J Infect Dis 2013; 207: 497-500.
16. Rossi-Tamisier M, Moal V, Gerolami R, Colson P. Discrepancy between anti-hepatitis E virus immunoglobulin G prevalence assessed by two assays in kidney and liver transplant recipients. J Clin Virol 2013; 56: 62-64.
17. Pischke S, Stiefel P, Franz B, et al. Chronic hepatitis E in heart transplant recipients. Am J Transplant 2012; 12: 3128-3133.
18. Hofmann H. Holzmann H [Incidence of hepatitis E in Austria.]. Wien Klin Wochenschr 1995; 107: 336-339.
19. Zaaijer HL, Yin MF, Lelie PN. Seroprevalence of hepatitis E in The Netherlands. Lancet 1992; 340: 681.
20. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012; 379: 2477-2488.
21. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140: 1481-1489.
22. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 401-412.
23. Mansuy JM, Huynh A, Abravanel F, Recher C, Peron JM, Izopet J. Molecular evidence of patient-to-patient transmission of hepatitis E virus in a hematology ward. Clin Infect Dis 2009; 48: 373-374.
24. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403.
25. Kamar N, Rostaing L, Abravanel F, et al. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology 2010; 139: 1612-1618.
26. Fuehner T, Dierich M, Duesberg C, et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antivir Ther 2012; 16: 733-740.